DSM-Firmenich stock
Price history
+47.20% over the period1 year: from €70.72 (November 17, 2025) to €104.10 (November 16, 2026), +47.20%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €104.10 |
| October 30, 2026 | €106.75 |
| September 30, 2026 | €97.58 |
| August 31, 2026 | €95.74 |
| July 31, 2026 | €93.38 |
| June 30, 2026 | €83.00 |
| May 29, 2026 | €72.16 |
| April 30, 2026 | €63.56 |
| March 31, 2026 | €61.44 |
| February 27, 2026 | €60.44 |
| January 30, 2026 | €66.20 |
| December 31, 2025 | €68.76 |
| November 28, 2025 | €70.76 |
| November 17, 2025 | €70.72 |
At a glance
The company
Provides nutrition, health, and beauty solutions including fragrances, food ingredients, vitamins, and pharmaceutical ingredients globally
Latest results
Quarter to June 30, 2026 · EPS €0.88 (estimate €0.91)
TickerLandia's take on DSM-Firmenich
- Pricier than similar companies: trailing 12-month P/E 63 vs 42 (+52%) in a group of 11.
- Strong point: Market momentum (91/100 in its group). Weak point: Profitability (18/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.24% from the 52-week high
Analysts · 20 analysts
Average target€102.12−1.90% vs. price
Buy 7 · Hold 12 · Sell 1 · Buy
TickerLandia Fingerprint: DSM-Firmenich
Compared with similar companies: very strong momentum, very low profitability, and very low earnings stability.
Financials and price compared with 59 companies in the specialty chemicals industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh68
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 21.7 78 Price/book 1.48 29 Price/sales 2.85 71 P/E (trailing 12 months) 63.4 88 Forward P/E 25.2 73 Profitabilityvery low18
How much it earns on revenue and capital.
Metric Value Position in group ROE 1.9% 9 ROA 1.2% 4 Net margin −15.2% 1 Gross margin 39.2% 60 Operating margin 6.8% 14 Earnings stabilityvery low19
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.9% 18 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 21 Growthlow32
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −56.20% 14 Average revenue growth (3 years) +2.50% 67 Revenue growth (year over year) +0.50% 14 Financial strengthaverage44
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 4.08 21 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.40 33 Debt/equitycounts in reverse: lower means more financial strength 0.38 72 Current ratio 1.75 48 Dividendaverage53
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 2.4% 59 Payout ratiopays out more than its earnings 206.6% 92 Consecutive dividend years at least 4 years 8 Market momentumvery strong91
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +14.27% 88 Relative strength (6 months) +41.10% 96 1-year return +44.34% 85 Distance from 200-day average +31.82% 96 Riskaverage49
How much the price swings.
Metric Value Position in group Beta (1 year) 0.73 48 Volatility (60 days) 26.7% 48 Maximum drawdown (12 months) 24.2% 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
DSM-Firmenich is pricier than similar companies
DSM-Firmenich's P/E (trailing 12 months): 63.4, +52% against the median of a group of 11 similar companies (41.7).
Compared with 11 similar companies
| Metric | DSM-Firmenich | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 63.4 | High | |
| Forward P/E | 25.2 | Middle | |
| Operating margin | 6.8% | Low | |
| ROE | 1.9% | Low | |
| Debt/equity | 0.38 | Middle |
Grey band: the middle half of the group; tick: the median; dot: DSM-Firmenich. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€4.66B
Latest quarter · Q2 2026
Net income
€212M
Latest quarter · Q2 2026
Quarterly net margin
4.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €25.8B
- P/E
- 63.4
- EPS
- -€5.36
- Volume
- 338K
- Daily trading
- €64.41M
- Dividend yield
- 2.38%
- Last ex-dividend on May 11, 2026
How DSM-Firmenich is changing
All resultsRevenue grew 2.2% a year on average over the last 5 years
Shares outstanding up 50.4% in 5 years
Profitable in 4 of 5 fiscal years
Returns
DSM-Firmenich returns with dividends
€1,000 invested in DSM-Firmenich 3 years ago, on November 16, 2023, would be worth €1,237 today with dividends reinvested: +23.72% in total, +7.35% per year. On price alone it would be €1,132 (+13.21%).
| Period | DSM-Firmenich | AEX | €1,000 becomes |
|---|---|---|---|
| 1 month | −2.76% | +1.03% | €972 |
| 6 months | +57.73% | +12.92% | €1,577 |
| Year to date | +51.40% | +19.94% | €1,514 |
| 1 year | +52.82% | +20.69% | €1,528 |
| 3 years | +23.72% | +51.34% | €1,237 |
Over the last 6 months it has done better than 95% of the stocks in the Consumer sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. AEX: price only. Calculate your investment
The chart in detail
DSM-Firmenich: technical analysis
DSM-Firmenich is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 15.8% below its all-time closing high (€123.65, September 30, 2024).
- Trend
- Upward
- RSI (14 sessions)
- 47
- Between 30 and 70
- vs 200-session average
- +29.66%
Support and resistance
Price areas where DSM-Firmenich has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€104.10
- Support€96.42−7.38%2 touches, last on November 4, 2026
- Support€94.37−9.35%2 touches, last on October 2, 2026
- Support€86.89−16.53%3 touches, last on August 18, 2026
Volatility and risk
Over the last year it has moved less than the AEX.
- Beta (1 year) vs AEX
- 0.72
- Volatility (60 sessions, annualised)
- 26.9%
- Largest fall in the last year
- −22.53%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
DSM-Firmenich and its competitors
DSM-Firmenich AG operates through three segments: Perfumery & Beauty, which creates scents from natural, synthetic and biotech ingredients; Taste, Texture & Health, which supplies flavors, natural extracts, food enzymes, hydrocolloids, cultures, natural colorants and plant-based proteins to food and beverage makers; and Health, Nutrition & Care, which offers vitamins, nutritional lipids, probiotics and prebiotics, active pharmaceutical ingredients and biomedical solutions to dietary supplement, pharmaceutical, early life and medical nutrition markets.
- Headquarters
- Kaiseraugst, Switzerland
- Employees
- 20,786
- Founded
- 1902
- Chief executive
- Dimitri de Vreeze
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DSM-FirmenichDSFIR | $28.52B | 6.8% | 63.4 | +57.73% |
| NovozymesNSIS.B | $31.63B | 23.4% | 42.1 | +20.47% |
| EMS-CHEMIE HOLDINGEMSN | $23.88B | 29.9% | 42.3 | +28.25% |
| SikaSIKA | $36.73B | 13.6% | 29.6 | +38.19% |
| GivaudanGIVN | $45.03B | 17.9% | 39.8 | +51.26% |
| SymriseSY1 | $14.06B | 12.6% | 52.6 | +29.50% |
Same industry or related industries, similar size. Compare DSM-Firmenich with its competitors · Full profile
